Evaluation of MN-221 (Bedoradrine), a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist in Mild to Moderate Asthma via Intravenous Infusion

Trial Profile

Evaluation of MN-221 (Bedoradrine), a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist in Mild to Moderate Asthma via Intravenous Infusion

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs Bedoradrine (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Nov 2012 Results published in the the Journal of Asthma, according to a MediciNova media release.
    • 09 Oct 2007 Primary endpoint achieved; results reported by MediciNova.
    • 09 Oct 2007 Status changed from initiated to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top